Release date: 2016-11-02
A group of frequently cited data is that the five-year survival rate of cancer patients in the United States is more than 68%. In contrast, the China Cancer Statistics Office published in January 2014, the China Cancer Statistics Annual Report: China Cancer Patients The annual survival rate is only about 25%.
However, intermediaries that provide domestic medical resources to foreign countries are trying to "turn around." On October 28th, SMI announced its entry into the field of post-natal rehabilitation health management services. For the institutions like SMI that have entered China for many years, “turning around†is not only an inevitable attempt to enter multiple subdivided medical service markets, but also a helpless move that is forced by the current overseas medical market.
Still a minority choice
Fang Ming, a doctor at the USS Sartre Hospital and John Muir Medical Center, pointed out: "Clinical medicine China and the United States have their own advantages, and the treatment skills themselves are not different to some extent. But the treatment survival rate of American tumors is double that of China. This is an interdisciplinary collaborative process involving immunization, pathology, surgery, imaging, etc. Which part of the problem will affect the final result. And the technical level of American doctors is also more average than China."
"In the past few years, we have brought domestic patients to seek medical treatment abroad. Later, we tried to bring overseas doctors to China for treatment. We found that the efficiency of medical treatment and the amount of medical treatment have improved. Now we have set up medical centers directly in China, and gradually chained At the same time, it has established cooperation with more and more medical institutions in China.†SMI’s executive chairman in China, Lin Gang, told the 21st Century Business Herald.
SMI belongs to SMI Swiss Medical Investment International Group, which was formerly known as the Geneva Medical Association of Switzerland. Eight years ago, SMI officially entered China, and overseas medical services were the first area of ​​its entry.
In China's overseas medical market, traditional third-party service organizations start early and in large numbers, mainly through the authorization of foreign medical institutions, introducing domestic patients to cooperative institutions, and providing services such as accompanying and postoperative follow-up.
As a purely service industry, the threshold for overseas medical treatment is not high, and the competitive landscape is chaotic. As a result, third-party service organizations hold many overseas top medical resources, but their role is limited.
Lin Gang further pointed out: "Now the main target audience for overseas medical treatment is cancer and other serious diseases. The lifeline is suspended and the domestic can not be treated. In addition, it is chronic diseases, gynecological tumors, etc. Cancer tumors are looking for the United States, rehabilitation, health management, etc. Looking for Europe, France, Switzerland, Italy, etc., the medical examination is Japan and other countries."
For third-party organizations in the field of overseas medical treatment, the core competitiveness lies in the number of cooperative hospitals, hospital rankings and qualifications, and service levels.
Depending on the content of the fee, the revenue of the third-party organization comes from the appointment service and ancillary services, including helping to select medical institutions and doctors, designing itineraries according to the individual needs of customers, handling medical visas, translating materials, airport transfers and accommodation arrangements. Overseas air rescue and so on. According to incomplete statistics, the number of third-party institutions providing such overseas medical services in China exceeds 1,000.
"But the simple docking is of little significance. The evaluation system of foreign hospitals and patients is relatively perfect. Many patients can also connect with international hospitals on their own, and the entry threshold is relatively low. Now there is no relevant regulation or regulation, which is spontaneous management. "SMI's executive chairman in China, Mr. Yan Guangzhong said frankly.
Yan Guangzhong told the 21st Century Business Herald that the number of overseas tumor surgeries is at least 200,000 to 300,000, and the total cost of patients is millions, and the cost of services is much higher than the cost of surgery. Even so, "the agency's revenue is still very low, with an average of 100 patients who come to consult, only 2 - 3 will choose to go abroad for treatment."
Transformation: helplessness and necessity
The uneven quality of domestic third-party organizations is also a headache.
The "Analysis and Analysis Report on Overseas Medical Intermediary Industry" provided by the Unicorn Studio pointed out that there is no mandatory regulation for the end of overseas medical treatment, resulting in a large difference in service and price. The overseas medical treatment population is quite special, mainly relying on the way of enterprise cooperation, and the cost of obtaining customers is relatively high.
Four years ago, SMI began to try to "turn around", on the one hand set up a medical center in China, on the one hand launched a tumor fund to deep into the patient population.
There are not a few third-party service organizations that extend the service content like SMI. Among them, Houpu Ark has established a wholly-owned subsidiary overseas, established a direct service team, built a self-built fleet, self-operated Houpu home apartment, and provided 24-hour hospitalization. The Shenguo family is transforming into a medical institution, building an international medical diagnostic center, and providing one-stop diagnostic programs and treatment programs for Chinese critically ill patients with international medical resources.
The "Overseas Medical Intermediary Industry Evaluation and Analysis Report" predicts that in the future, third-party organizations will no longer be limited to overseas intermediary medical services, but will deepen medical attributes and provide professional services in consulting, nursing, and post-treatment management.
In addition, overseas medical treatment prices will become more transparent. Many small companies will merge or withdraw from overseas medical treatment, and eventually there will be a number of giant companies coexisting, but there will be no monopoly.
(Original title: Overseas medical treatment: 2%-3% of patients' choice)
Source: Health Point
Plant extracts are based on plants as raw materials. According to the needs of the use of the final product extracted, through a physical and chemical extraction and separation process, one or more effective ingredients in the plant are obtained and concentrated, without changing the effective ingredients. The product formed by the structure.
1. According to the content of active ingredients, it can be divided into three types: effective monomer extract, standard extract and ratio extract;
2. Divided into glycosides, acids, polyphenols, polysaccharides, terpenes, flavonoids, alkaloids, etc. according to ingredients;
3. According to the product form, it can be divided into vegetable oil, extract, powder, lens, etc.
4. According to the purpose, plant extracts can be divided into natural pigment products, traditional Chinese medicine extract products, extract products and concentrated products.
There are several classifications of some of the best-selling plant extracts in the world. For example, Rhodiola, Ginkgo biloba, Ginseng extracts are used in the field of brain strengthening, nourishment, and prevention and treatment of Alzheimer's; polypeptide extracts of green tea, Citrus aurantium, apple, and bitter gourd Used in weight loss, lowering blood sugar and preventing diabetes; Paclitaxel, tea polyphenols, theanine, bioflavonoids, such as lycopene, anthocyanins, etc. are used in natural anti-cancer fields; licorice, garlic, astragalus, soybean extract Used in the field of human immune system.
Plant extract,milk thistle extract,Quercetin,mushroom extract,rutin
PYSON Co. ,Ltd. , https://www.pysonbio.com